Biogen Idec ( BIIB +0.1% ) will report Q3 results before the open on October 22. The conference call will start at 9:00 am ET. Consensus view is EPS of $3.45 on revenues of $2.5B. Post your comment!
Asset Management and Research : Biogen Idec BIIB reported strong second quarter ..... revisions and growth estimates, Biogen Idec still offers investors strong upside potential. About The Company Biogen Idec discovers, develops, manufactures
By Arie Goren : Biogen Idec Inc . (NASDAQ: BIIB ) will continue to benefit ..... Nevertheless, in my opinion, BIIB 's stock still has room to move up. Biogen has decent valuation ..... margin. The Company Biogen Idec is one of the world
of large, powerful bio-pharmas. The others are Gilead (NASDAQ: GILD ), Regeneron (NASDAQ: REGN ) and Biogen Idec (NASDAQ: BIIB ). Management is deep and well-respected. Chairman / CEO Robert Hugin has executive experience within the
of meaningful worsening in the physical impact of MS was reduced 24% compared to the Avonex cohort. Development partners Biogen (NASDAQ: BIIB ) and AbbVie (NYSE: ABBV ) plan to submit regulatory applications for Zinbryta in 1H 2015. Post your comment!
has strategic alliances with a number of companies, such as Hanmi Pharmaceuticals, Ligand Pharmaceuticals, Bayer, Biogen Idec , Mundipharma, TopoTarget, Fujifilm, Inex, Hansdok and Nippon Kayaku. The company acquires late-stage products
Pharmaceuticals ( ISIS -3.1% ) discloses that it earned an $18M milestone payment from development partner Biogen Idec ( BIIB -1.1% ) by virtue of dosing the first infant in the ENDEAR Phase 3 clinical trial evaluating ISIS-SMNrx as
The FDA approves Biogen Idec 's (NASDAQ: BIIB ) Plegridy ( peginterferon beta-1a ) for the treatment of patients with relapsing forms of multiple sclerosis (MS). It is
NEW YORK, AUG 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc 's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older...
Aug 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc 's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling...